Has Inflammation a Significant Implication in Lung Cancer Evolution?

European Lung Cancer Working Party

Status: Unknown

Conditions: Lung Neoplasms

Study type: Observational

Funder types: Other

Identifiers

NCT02484872

ELCWP01501

Details and patient eligibility

About

Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of the study is to look at the prognostic and predictive value of inflammation during cancer evolution, on the risk of complications leading to ICU admission and the risk of death.

Full description

Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and in case of complication.

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Lung neoplasms irrespective of stage, histology

Exclusion criteria

• Previously treated lung neoplasms
• A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free interval)

Trial design

400 participants in 1 patient group

Lung neoplasms

Description:

Lung neoplasms irrespective of stage and histology